JP2020518629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518629A5 JP2020518629A5 JP2019560313A JP2019560313A JP2020518629A5 JP 2020518629 A5 JP2020518629 A5 JP 2020518629A5 JP 2019560313 A JP2019560313 A JP 2019560313A JP 2019560313 A JP2019560313 A JP 2019560313A JP 2020518629 A5 JP2020518629 A5 JP 2020518629A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- day
- dose
- midh2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 9
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 206010028537 myelofibrosis Diseases 0.000 claims description 4
- 208000037244 polycythemia vera Diseases 0.000 claims description 4
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 108700028369 Alleles Proteins 0.000 claims 7
- 229940125904 compound 1 Drugs 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 7
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 5
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 5
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical group C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 4
- 229960000215 ruxolitinib Drugs 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 206010014950 Eosinophilia Diseases 0.000 claims 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 206010072206 Janus kinase 2 mutation Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
Images
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502456P | 2017-05-05 | 2017-05-05 | |
| US62/502,456 | 2017-05-05 | ||
| US201762535146P | 2017-07-20 | 2017-07-20 | |
| US62/535,146 | 2017-07-20 | ||
| PCT/US2018/031090 WO2018204787A1 (en) | 2017-05-05 | 2018-05-04 | Methods of treatment of myeloproliferative neoplasm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518629A JP2020518629A (ja) | 2020-06-25 |
| JP2020518629A5 true JP2020518629A5 (https=) | 2021-07-01 |
Family
ID=62245425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560313A Pending JP2020518629A (ja) | 2017-05-05 | 2018-05-04 | 骨髄増殖性腫瘍の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11229653B2 (https=) |
| EP (1) | EP3618828B1 (https=) |
| JP (1) | JP2020518629A (https=) |
| ES (1) | ES2968376T3 (https=) |
| WO (1) | WO2018204787A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204787A1 (en) * | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020135401A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN113129017B (zh) * | 2020-08-31 | 2022-06-24 | 支付宝(杭州)信息技术有限公司 | 一种信息共享方法、装置及设备 |
| JP2024504367A (ja) * | 2021-01-22 | 2024-01-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんを治療及び改善するための方法 |
| WO2024031406A1 (en) * | 2022-08-10 | 2024-02-15 | Xiang Li | Idh mutations as biomarkers for zotiraciclib therapy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2913401A (en) | 1957-04-19 | 1959-11-17 | Exxon Research Engineering Co | Hydrogen production and hydroforming |
| DE3307071C2 (de) | 1983-03-01 | 1986-05-22 | Joachim Dr.-Ing. 7250 Leonberg Wünning | Durchlaufofen für die Wärmbehandlung von metallischen Werkstücken |
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| EP3561077B1 (en) | 2009-10-21 | 2022-12-21 | Les Laboratoires Servier | Methods for cell-proliferation-related disorders |
| NZ627096A (en) | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| MY185687A (en) | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| CA2993615A1 (en) | 2015-08-05 | 2017-02-09 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| CN108366980A (zh) | 2015-10-15 | 2018-08-03 | 安吉奥斯医药品有限公司 | 用于治疗恶性肿瘤的组合疗法 |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| ES2912909T3 (es) | 2016-02-26 | 2022-05-30 | Celgene Corp | Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria |
| WO2018204787A1 (en) * | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
-
2018
- 2018-05-04 WO PCT/US2018/031090 patent/WO2018204787A1/en not_active Ceased
- 2018-05-04 JP JP2019560313A patent/JP2020518629A/ja active Pending
- 2018-05-04 US US16/615,115 patent/US11229653B2/en active Active
- 2018-05-04 ES ES18727499T patent/ES2968376T3/es active Active
- 2018-05-04 EP EP18727499.8A patent/EP3618828B1/en active Active
-
2021
- 2021-12-16 US US17/553,588 patent/US11833154B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518629A5 (https=) | ||
| US20250375440A1 (en) | Composition and method of treating cancer associated with egfr mutation | |
| US20130252988A1 (en) | Compositions and methods for treating myelofibrosis | |
| KR20180058745A (ko) | 중수소화된 cftr 강화제의 투여 | |
| JP6805336B2 (ja) | 薬学的組み合わせ | |
| CN105848682A (zh) | 药物组合 | |
| EA037152B1 (ru) | Способ лечения рака | |
| JP2021152003A (ja) | イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物の安定化方法 | |
| CN107683138A (zh) | 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途 | |
| US11471456B2 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| US20210369709A1 (en) | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | |
| WO2014081712A2 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
| CN120857931A (zh) | 用于治疗患有血液学恶性病的患者的方法 | |
| CN118510517A (zh) | 用于治疗急性髓系白血病的flt3抑制剂和bcl-2抑制剂的治疗有效组合 | |
| CN111249282A (zh) | 癌症疗法 | |
| EP1893213B1 (en) | Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases | |
| JP2006508118A (ja) | 慢性リンパ性白血病の処置のためのナイトロジェンマスタードアナログとイマチニブの組み合わせ剤 | |
| RU2018114922A (ru) | Лечение очаговой алопеции | |
| JP6937308B2 (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| CN107206092A (zh) | 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基磺酰亚氨基)甲基]苯基}‑1,3,5‑三嗪‑2‑胺用于治疗白血病的用途 | |
| WO2017129087A1 (zh) | 一种含有喹啉衍生物或其盐的药物组合物 | |
| JP2019528260A5 (https=) | ||
| HK40058860B (en) | Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6- yl)amino)cyclohexyl)propan-2-ol | |
| CN107427520A (zh) | 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基磺酰亚氨基)甲基]苯基}‑1，3，5‑三嗪‑2‑胺用于治疗淋巴瘤的用途 | |
| HK1115528B (en) | Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases |